Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Dendritic Cell Recovery Impacts Outcomes after Umbilical Cord Blood and Sibling Donor Transplantation for Hematologic Malignancies.

Touma W, Brunstein CG, Cao Q, Miller JS, Curtsinger J, Verneris MR, Bachanova V.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1925-1931. doi: 10.1016/j.bbmt.2017.07.008. Epub 2017 Jul 17.

PMID:
28729150
2.

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts.

Brunstein CG, Cutler CS, DeFor TE, Kim H, Bejanyan N, Garfall A, Verneris MR, Chen YB, Warlick ED, Spitzer T, Miller JS, Antin JH, Weisdorf DJ, Soiffer R, Wagner JE, Ballen KK.

Biol Blood Marrow Transplant. 2017 Jan;23(1):126-133. doi: 10.1016/j.bbmt.2016.10.018. Epub 2016 Oct 29.

3.

Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.

McKenna DH Jr, Sumstad D, Kadidlo DM, Batdorf B, Lord CJ, Merkel SC, Koellner CM, Curtsinger JM, June CH, Riley JL, Levine BL, Miller JS, Brunstein CG, Wagner JE, Blazar BR, Hippen KL.

Cytotherapy. 2017 Feb;19(2):250-262. doi: 10.1016/j.jcyt.2016.10.011. Epub 2016 Nov 22.

4.

In the end, there can be only one … cord blood unit.

Brunstein CG.

Blood. 2016 Oct 27;128(17):2115. No abstract available.

5.

Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.

Bejanyan N, Rogosheske J, DeFor TE, Lazaryan A, Arora M, Holtan SG, Jacobson PA, MacMillan ML, Verneris MR, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2025-2030. doi: 10.1016/j.bbmt.2016.08.005. Epub 2016 Aug 9.

6.

Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International Blood and Marrow Transplant Research Survey.

Rafii H, Ruggeri A, Volt F, Brunstein CG, Carreras J, Eapen M, Gluckman E, Weisdorf DJ.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1717-1720. doi: 10.1016/j.bbmt.2016.05.015. Epub 2016 May 21. No abstract available.

7.

Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD.

Eckfeldt CE, Randall N, Shanley RM, Yohe S, Bejanyan N, Dolan M, Warlick ED, Verneris MR, Brunstein CG, Wagner JE, Weisdorf DJ, Ustun C.

Haematologica. 2016 Aug;101(8):e348-51. doi: 10.3324/haematol.2016.143628. Epub 2016 Apr 28. No abstract available.

8.

Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.

Sanghavi K, Wiseman A, Kirstein MN, Cao Q, Brundage R, Jensen K, Rogosheske J, Kurtzweil A, Long-Boyle J, Wagner J, Warlick ED, Brunstein CG, Weisdorf DJ, Jacobson PA.

Transl Res. 2016 Sep;175:103-115.e4. doi: 10.1016/j.trsl.2016.03.017. Epub 2016 Mar 31.

9.

Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.

Mehta RS, Peffault de Latour R, DeFor TE, Robin M, Lazaryan A, Xhaard A, Bejanyan N, de Fontbrune FS, Arora M, Brunstein CG, Blazar BR, Weisdorf DJ, MacMillan ML, Socie G, Holtan SG.

Haematologica. 2016 Jun;101(6):764-72. doi: 10.3324/haematol.2015.138990. Epub 2016 Apr 1.

10.

Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft.

Wagner JE Jr, Brunstein CG, Boitano AE, DeFor TE, McKenna D, Sumstad D, Blazar BR, Tolar J, Le C, Jones J, Cooke MP, Bleul CC.

Cell Stem Cell. 2016 Jan 7;18(1):144-55. doi: 10.1016/j.stem.2015.10.004. Epub 2015 Dec 5.

11.

Nonparametric methods for analyzing recurrent gap time data with application to infections after hematopoietic cell transplant.

Lee CH, Luo X, Huang CY, DeFor TE, Brunstein CG, Weisdorf DJ.

Biometrics. 2016 Jun;72(2):535-45. doi: 10.1111/biom.12439. Epub 2015 Nov 17.

12.

Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.

Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, Riley JL, June CH, Le C, Weisdorf DJ, McGlave PB, Blazar BR, Wagner JE.

Blood. 2016 Feb 25;127(8):1044-51. doi: 10.1182/blood-2015-06-653667. Epub 2015 Nov 12.

13.

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation.

Bachanova V, Rogosheske J, Shanley R, Burns LJ, Smith SM, Weisdorf DJ, Brunstein CG.

Biol Blood Marrow Transplant. 2016 Mar;22(3):571-4. doi: 10.1016/j.bbmt.2015.10.012. Epub 2015 Oct 21.

14.

Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation.

Brunstein CG, Petersdorf EW, DeFor TE, Noreen H, Maurer D, MacMillan ML, Ustun C, Verneris MR, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE.

Biol Blood Marrow Transplant. 2016 Mar;22(3):487-92. doi: 10.1016/j.bbmt.2015.09.025. Epub 2015 Sep 30.

15.

Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.

Lazaryan A, Weisdorf DJ, DeFor T, Brunstein CG, MacMillan ML, Bejanyan N, Holtan S, Blazar BR, Wagner JE, Arora M.

Biol Blood Marrow Transplant. 2016 Jan;22(1):134-40. doi: 10.1016/j.bbmt.2015.09.008. Epub 2015 Sep 11.

16.

The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.

Cichocki F, Verneris MR, Cooley S, Bachanova V, Brunstein CG, Blazar BR, Wagner J, Schlums H, Bryceson YT, Weisdorf DJ, Miller JS.

Curr Top Microbiol Immunol. 2016;395:225-43. doi: 10.1007/82_2015_445. Review.

17.

Wanted: prospective studies of alternative donors.

Brunstein CG.

Biol Blood Marrow Transplant. 2015 Jun;21(6):957-8. doi: 10.1016/j.bbmt.2015.04.011. Epub 2015 Apr 15. No abstract available.

18.

Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation.

Bejanyan N, Rogosheske J, DeFor T, Lazaryan A, Esbaum K, Holtan S, Arora M, MacMillan ML, Weisdorf D, Jacobson P, Wagner J, Brunstein CG.

Biol Blood Marrow Transplant. 2015 May;21(5):926-33. doi: 10.1016/j.bbmt.2015.01.023. Epub 2015 Feb 3.

19.

Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood.

Hanley PJ, Bollard CM, Brunstein CG.

Cytotherapy. 2015 Jun;17(6):749-755. doi: 10.1016/j.jcyt.2014.12.007. Epub 2015 Jan 24. Review.

20.

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.

Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, Blazar BR, MacMillan ML, Weisdorf DJ.

Blood. 2015 Feb 19;125(8):1333-8. doi: 10.1182/blood-2014-10-609032. Epub 2015 Jan 15.

Supplemental Content

Loading ...
Support Center